If it works, it will still not benefit the poor investors at NewCyte who sold their company to NXT for warrants only. No cash consideration. Their warrants expired worthless in Dec 2012. NewCyte had lots of directors in common with NXT, like Flood and Barron.
They haven't even done animal tests yet although I wonder what is comparable in vision with dogs in the vision department, so it is a long time from market. Since there really isn't any useful alternative treatment perhaps they qualify for the FDA's hurry-up offence program which is still a plodding route.
News 
Market Data 
Discover 
AI
